Fas-ligand staining in non-drug- and drug-induced maculopapular rashes

Journal of Cutaneous Pathology

Volumn 38, Issue 2, 2011, Pages 196-201

  Wang, Etienne C E ^a   Lee, Joyce S S ^a   Tan, Audrey W H ^a   Tang, Mark B Y ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FAS LIGAND; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; RASH; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EXANTHEMA; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 78650676384     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2010.01611.x     Document Type: Article

References (16)

1. Bigby M., Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765.
2. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H., Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162: 1515.
3. Stur K, Karlhofer FM, Stingl G., Soluble Fas ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007; 127: 802.
4. Viard I, Wehrli P, Bullani R, et al., Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490.
5. Bronnimann M, Yawalkar N., Histopathology of drug-induced exanthems: Is there a role in diagnosis of drug allergy? Curr Opin Allergy Clin Immunol 2005; 5: 317.
6. Pichler WJ., Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683.
7. Park HJ, Kim HS, Kim HJ, et al., Immunohistochemical characterization of cutaneous drug eruptions by STI571. J Dermatol Sci 2005; 38: 9.
8. Klein J, Horejsi V., Defence against invaders. In, Klein J, Horejsi V, eds. Immunology, 2nd ed. Oxford: Blackwell Science, 1997; 532.
9. Hari Y, Urwyler A, Hurni M, et al., Distinct serum cytokine levels in drug and measles induced exanthema. Int Arch Allergy Immunol 1998; 120: 225.
10. Torres MJ, Corzo JL, Levya L, et al., Difference in the immunological responses in drug- and virus-induced cutaneous reactions in children. Blood Cells Mol Dis 2003; 30: 124.
11. Yawalkar N, Shrikhande M, Harl Y, Nievergelt H, Braathen LR, Pichler WJ., Evidence for a role of IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106: 1171.
12. Lee SH, Jang JJ, Lee JY, et al., Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br J Dermatol 1998; 139: 186.
13. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505.
14. Ferguson TA, Griffith TS., A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 2006; 213: 228.
15. Satchell A, Barnetson R, Halliday G., Increased Fas ligand expression by T-cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. Br J Dermatol 2004; 151: 42.
16. Trautmann A, Akdis M, Kleeman D, et al., T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenic role in eczematous dermatitis. J Clin Invest 2000; 106: 25.